• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ligand Pharm (NQ: LGND )

    111.13 +0.91 (+0.83%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ligand Pharm

    < Previous 1 2 3 4 5 6 Next >
    Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Earnings Scheduled For February 27, 2024
    Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
    Via Benzinga
    Ligand Pharmaceuticals's Earnings: A Preview
    Via Benzinga
    Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
    Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024. 
    Via Benzinga
    Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
    Via Benzinga
    Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session
    Via Investor Brand Network
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
    From Palvella Therapeutics
    Via GlobeNewswire
    Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
    Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent  
    Via Benzinga
    Ligand Reports Third Quarter 2023 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand To Report Third Quarter 2023 Financial Results On November 8
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ligand Acquires Assets of Novan, Inc. for $12.2 Million
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Appoints Martine Zimmermann to its Board of Directors
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
    Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.